TY - JOUR
T1 - The forgotten survivor
T2 - A comprehensive review on Non-Hodgkin lymphoma survivorship
AU - Alabdaljabar, Mohamad S.
AU - Durani, Urshila
AU - Thompson, Carrie A.
AU - Constine, Louis S.
AU - Hashmi, Shahrukh K.
N1 - Funding Information:
None relevant. SKH has received honoraria from Novartis, Mallinckrodt, Pfizer, and Janssen. SKH has received travel grants from MSD, Gilead, Sanofi, and Amgen. LSC: none relevant. CAT: none.
Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2022/12
Y1 - 2022/12
N2 - The number of non-Hodgkin lymphoma (NHL) survivors is increasing. With the advancement of NHL therapies, it is crucial to focus on the challenges these survivors may face. Three main categories are to be considered in NHL survivorship, including quality of life and uncertainty about the future, possible physical health complications (including cardiovascular disease, infertility, and subsequent neoplasms), and the impact of novel NHL treatments and their potential complications. The latter includes CAR T-cell therapy, monoclonal antibodies, checkpoint inhibitors, and hematopoietic stem cell transplantation. In this report, we aim to shed the light on these aspects and to discuss survivorship care plan for NHL.
AB - The number of non-Hodgkin lymphoma (NHL) survivors is increasing. With the advancement of NHL therapies, it is crucial to focus on the challenges these survivors may face. Three main categories are to be considered in NHL survivorship, including quality of life and uncertainty about the future, possible physical health complications (including cardiovascular disease, infertility, and subsequent neoplasms), and the impact of novel NHL treatments and their potential complications. The latter includes CAR T-cell therapy, monoclonal antibodies, checkpoint inhibitors, and hematopoietic stem cell transplantation. In this report, we aim to shed the light on these aspects and to discuss survivorship care plan for NHL.
UR - http://www.scopus.com/inward/record.url?scp=85139002435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139002435&partnerID=8YFLogxK
U2 - 10.1002/ajh.26719
DO - 10.1002/ajh.26719
M3 - Review article
C2 - 36069675
AN - SCOPUS:85139002435
SN - 0361-8609
VL - 97
SP - 1627
EP - 1637
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 12
ER -